Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies
- 1Department of Emergency Medicine, The Second Affiliated Hospital, University of South China
- 2Department of Clinical Medicine, Changsha Medical University
- 3Department of Geriatrics, Shaoyang Central Hospital
Abstract
Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, with the EWSR1-FLI1 fusion gene serving as its core driver event. Although multi-agent chemotherapy has achieved nearly 70% five-year survival in patients with localized disease, the prognosis for those with metastatic or relapsed/refractory disease remains poor, with long-term survival rates below 30%, and no substantial breakthrough has been made in first-line regimens over the past decade. Immune checkpoint inhibitors have revolutionized the treatment landscape for various adult solid tumors, but their efficacy in Ewing sarcoma—a typical “cold” tumor—is limited, owing to its low tumor mutational burden, sparse neoantigens, and highly immunosuppressive microenvironment. Recent studies suggest that EWSR1-FLI1 not only reshapes transcriptional programs but also functions as a metabolic “master switch, “ driving enhanced glycolysis, altered glutamine and tryptophan metabolism, and lipid metabolic remodeling. These metabolic alterations, in turn, produce lactate, kynurenine, lipid mediators, and local hypoxia, which suppress effector T cells and natural killer cells, induce regulatory T cells, and polarize macrophages toward a protumor phenotype, thereby forming a self-reinforcing causal chain between metabolism and immunity. This review systematically delineates this chain—from fusion-driven metabolic reprogramming, through metabolism-mediated immunosuppressive mechanisms, to intervention strategies targeting the metabolism–immunity interface. We focus on glycolysis inhibition, blockade of the tryptophan–AHR axis, lipid metabolism interventions, as well as novel surface targets (B7-H3, STEAP1, ENPP1, IL1RAP, MIF-CD74) for cell-based therapies and combination strategies of metabolic modulation with immunotherapy. We further analyze the practical obstacles to translating these strategies into clinical practice and, based on a critical synthesis of available evidence, Propose a metabolic–immune coupling model anchored on the active state of EWS-FLI1 to explain plasticity-driven resistance. This model provides a translational roadmap grounded in metabolic subtyping with the goal of “converting cold tumors to hot, “ offering a new framework for improving outcomes in Ewing sarcoma.
Related
- Immune cell metabolic reprogramming in pancreatic cancer: roles in tumor progression and therapeutic strategies
- Editorial: The differentiation and reprogramming of tumor-associated myeloid cells and therapeutic strategies for cancer immunotherapy
- Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity
- Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities
- Rewiring the breast cancer immune microenvironment through non-coding RNA-macrophage crosstalk: therapeutic vulnerabilities for immune reprogramming
BibTeX
@article{tang2026metabolic,
title = {{Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies}},
author = {Lingyun Tang and Haoling Zhou and Jia Liu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1962178},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962178/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies
AU - Lingyun Tang
AU - Haoling Zhou
AU - Jia Liu
PY - 2026
DA - 2026/10/28
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1962178
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962178/full
AB - Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, with the EWSR1-FLI1 fusion gene serving as its core driver event. Although multi-agent chemotherapy has achieved nearly 70% five-year survival in patients with localized disease, the prognosis for those with metastatic or relapsed/refractory disease remains poor, with long-term survival rates below 30%, and no substantial breakthrough has been made in first-line regimens over the past decade. Immune checkpoint inhibitors have revolutionized the treatment landscape for various adult solid tumors, but their efficacy in Ewing sarcoma—a typical “cold” tumor—is limited, owing to its low tumor mutational burden, sparse neoantigens, and highly immunosuppressive microenvironment. Recent studies suggest that EWSR1-FLI1 not only reshapes transcriptional programs but also functions as a metabolic “master switch, “ driving enhanced glycolysis, altered glutamine and tryptophan metabolism, and lipid metabolic remodeling. These metabolic alterations, in turn, produce lactate, kynurenine, lipid mediators, and local hypoxia, which suppress effector T cells and natural killer cells, induce regulatory T cells, and polarize macrophages toward a protumor phenotype, thereby forming a self-reinforcing causal chain between metabolism and immunity. This review systematically delineates this chain—from fusion-driven metabolic reprogramming, through metabolism-mediated immunosuppressive mechanisms, to intervention strategies targeting the metabolism–immunity interface. We focus on glycolysis inhibition, blockade of the tryptophan–AHR axis, lipid metabolism interventions, as well as novel surface targets (B7-H3, STEAP1, ENPP1, IL1RAP, MIF-CD74) for cell-based therapies and combination strategies of metabolic modulation with immunotherapy. We further analyze the practical obstacles to translating these strategies into clinical practice and, based on a critical synthesis of available evidence, Propose a metabolic–immune coupling model anchored on the active state of EWS-FLI1 to explain plasticity-driven resistance. This model provides a translational roadmap grounded in metabolic subtyping with the goal of “converting cold tumors to hot, “ offering a new framework for improving outcomes in Ewing sarcoma.
SN - 1664-3224
ER -